Abstract
Ovarian cancer is a kind of cancer from the female genital tract; the molecular mechanism still needs to be explored. lncRNA plays a vital role in tumorigenesis and development. Our aim was to identify oncogenic lncRNAs in ovarian cancer and explore the potential molecular mechanism. SNHG15 was initially identified by using GEO datasets (GSE135886 and GSE119054) and validated by tumor tissues and the cell line, identifying that SNHG15 was upregulated in ovarian cancer. Besides, high SNHG15 indicated poor prognosis in ovarian cancer. Furthermore, knockdown SNHG15 suppresses ovarian cancer proliferation and promotes apoptosis. Mechanistically, SNHG15 promotes proliferation through upregulated CDK6 via sponging miR-370-3p. Taken together, our findings emphasize the important role of SNHG15 in ovarian cancer, suggesting that SNHG15 may be a promising target for ovarian cancer.
Highlights
Ovarian cancer is the leading fatal neoplasm of the female genital tract [1,2,3]
We initially identified that SNHG15 was upregulated in ovarian cancer based on published data, and we validated it in tumor tissues and cell lines
The results showed that SNHG15 was upregulated and predicted poor prognosis in ovarian cancer; in addition, SNHG15 promoted cancer cell proliferation through upregulated CDK6 via inhibited mir-370-3p
Summary
Ovarian cancer is the leading fatal neoplasm of the female genital tract [1,2,3]. Ovarian cancer affects annually 295414 new patients, with approximately 184799 deaths/year [4]. The mechanism of ovarian cancer occurrence and new strategies of treatment still need to be explored. With the deepening of research in recent years, people’s cognition of lncRNAs has been consistently improved and a large amount of evidence suggests that lncRNA has become an indispensable participant in the development of different human tumors [8,9,10]; for instance, HOTAIR promotes hepatocellular carcinoma progression [11] and regulated leukemia differentiation [12]; H19 promotes glioma angiogenesis [13] and promotes leukemogenesis [14]; MEG3 inhibits prostate cancer progression [15] and regulates imatinib resistance in chronic myeloid leukemia [16]. LncRNA may be a promising therapeutic target in treating tumors, including ovarian cancer; there is a great need to identify lncRNAs to provide a new treatment strategy for ovarian cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
